Head and neck squamous cell carcinoma (HNSCC) is a mucosal malignancy arising from the paranasal sinuses, nasal cavities, oral cavity, nasopharynx, oropharynx, hypopharynx, and larynx, and it is used here as a study disease for prognosis stratification and immuno-oncology research. It is a major setting for evaluating f2rl1 as a prognostic and immuno-modulatory factor, alox15 as a tumor-suppressive, downregulated gene, and cd274 editing to improve tumor immunogenicity. The disease is also central to treatment studies involving radiation therapy, pembrolizumab, photoimmunotherapy, and ace imac, reflecting both standard locoregional management and emerging immune-based approaches. Recent literature highlights that single-agent immunotherapy often fails in this cancer, while perioperative pembrolizumab plus standard of care has been assessed in resectable locally advanced disease. Additional advances include optogenetic CD274 editing, ACE-expressing macrophage therapy reducing xenograft tumor size, and radiation-driven remodeling of systemic and intratumoral T-cell populations.
Prognosis and immune biomarkers
- f2rl1 was evaluated in head and neck squamous cell carcinoma for expression, clinical outcomes, and immune associations, supporting its role as a prognostic and immuno-modulatory factor. (PMID:41868802)
- A 2026 PeerJ study (PMID:41868802) linked f2rl1 with clinicopathologic and immune features in HNSCC.
- alox15 was reported as downregulated in HNSC and associated with clinicopathological parameters, consistent with a tumor-suppressive role via the ERK pathway. (PMID:41820595)
- The disease context was used to assess AI-based biomarker and outcome prediction in a 2026 review of HNSCC. (PMID:41593888)
Immunotherapy and immune engineering
- Single-agent immunotherapy was noted to often fail to produce responses in this cancer, motivating combination and engineered approaches. (PMID:41702512)
- Perioperative pembrolizumab plus standard of care was evaluated for resectable locally advanced HNSCC in a 2026 Journal of Medical Economics analysis. (PMID:41730003)
- Optogenetic cd274 editing in HNSCC cells was used to enhance photoimmunotherapy by improving immunogenicity. (PMID:41624538)
- ACE-expressing ACE-iMac immunotherapy reduced solid tumor size in HNSCC xenografts, supporting macrophage-based immunotherapy. (PMID:41968179)
Radiation and locoregional management
- radiation therapy remains a central component of management for locoregional head and neck squamous cell carcinoma. (PMID:41984232)
- A 2026 Cancer Immunology, Immunotherapy study showed radiation-induced remodeling of systemic and intratumoral T-cell populations in head and neck cancer. (PMID:41984232)
- The disease was used as the context for evaluating enhanced photoimmunotherapy in a biomimetic nanoplatform study. (PMID:41624538)
- HNSCC was also used as the solid tumor model for xenograft testing of ACE-iMac immunotherapy. (PMID:41968179)